Evandro de Azambuja - Concepedia

Author

Evandro de Azambuja

Also Known As

E Azambuja, E De Azambuja, E de Azambuja, E. AZAMBUJA, E. Azambuja, E. De Azambuja, E. de Azambuja, E.D. Azambuja, EVANDRO DE AZAMBUJA, Evandro Azambuja

720

Publications

37.4K

Citations

H-Index

Concepts

All Affiliations

Institut Jules Bordet Université Libre de Bruxelles Breast International Group European Institute of Oncology Dana-Farber Cancer Institute

About

Evandro de Azambuja is an author at Institut Jules Bordet specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	73	11.7K
2	Health Sciences	19	22	3.4K
3	Public Health	10	10	1.3K
4	Nursing	2	2	217
5	Biostatistics	2	2	64

Evandro de Azambuja

164

Publications

26K

Citations

H-Index

Page 1

	Year	Citations
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, European Heart Journal	2022	2.4K
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Sherene Loi, Nicolas Sirtaine, Fanny Piette, Journal of Clinical Oncology	2013	1.6K
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer Andrew Tutt, Judy E. Garber, Bella Kaufman, New England Journal of Medicine	2021	1.6K
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja, New England Journal of Medicine	2017	1.4K
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial José Baselga, Ian Bradbury, Holger Eidtmann, The Lancet Breast OncologyOncologyPathologyBreast CancerCancer Treatment	2012	1.3K
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Alessandra Gennari, Fabrice André, Carlos H. Barrios, Annals of Oncology Surgical OncologyMetastatic Breast CancerBreast OncologyMedicineCancer Management	2021	1.3K
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial David Cameron, Martine Piccart, Richard D. Gelber, The Lancet Herceptin AdjuvantBreast OncologyOncologyImmunologyAdjuvant Chemotherapy	2017	1K
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley, Annals of Oncology OncologyCardiovascular DiseaseCardiac DiseaseEsmo Consensus RecommendationsCancer Management	2020	950
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Giuseppe Curigliano, Daniela Cardinale, Thomas Suter, Annals of Oncology Radiation MedicineOncologyRadiation TherapyCardiovascular DiseasePharmacotherapy	2012	845
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours Émilie Le Rhun, Michael Weller, Dieta Brandsma, Annals of Oncology	2017	622

Page 1